Cardio-oncology & otherSecondary analysis
Atorvastatin and Myocardial Extracellular Volume Expansion During Anthracycline-Based Chemotherapy
- Secondary analysis of the STOP-CA randomised trial
- placebo-controlled
- CMR substudy
Authors' conclusion
Compared with placebo, atorvastatin limited ECV expansion among participants with lymphoma undergoing anthracycline chemotherapy.
Study context
- Population
- Patients with lymphoma treated with anthracycline-based chemotherapy127 analysed
- Participants
- 171 patients
- Comparison
- Atorvastatin vs placebo
- Primary endpoint
- ≥3% increase in myocardial ECV on CMR
- Follow-up
- 12 months
Primary result
≥3% increase in ECV
Odds ratio
0.20
95% CI 0.06–0.59
P = 0.002
By group
Atorvastatin vs Placebo
OR 0.20 (95% CI 0.06–0.59); P = 0.002
As reported in the abstract
Secondary outcomes
| Outcome | decrease in LVEF (95% CI) | P value |
|---|---|---|
| LVEF change associated with ≥3% ECV increase · follow-up | 8.4% (−6.31 to −10.38) | P < 0.001 |
≥1-SD increase in native T1 and T2 times · 12 months
- Statistically similar between groups
HF events, without vs with ≥3% extracellular volume (ECV) increase · 24 months
- Fewer HF events among those without ≥3% increases in ECV, not statistically significant
- 8% vs 24%; P = 0.054
Original publication
Atorvastatin and Myocardial Extracellular Volume Expansion During Anthracycline-Based Chemotherapy. JACC CardioOncol. Published 28 January 2025. doi:10.1016/j.jaccao.2024.11.008
Summarised from the published abstract; every number is checked against it